Weekly Digest – 17 to 23 August 2024

Regulatory  ·  Weekly Digest - 17 to 23 August 2024
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer

Weekly Digest – August 2024 Weekly Digest – August 2024 19 Aug 2024: ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer ENHERTU® has been granted Breakthrough Therapy Designation in the U.S. […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 17 to 23 August 2024
ENHERTU® Type II Variation Application Validated by EMA for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following At Least One Endocrine Therapy

Weekly Digest – August 2024 Weekly Digest – August 2024 19 Aug 2024: ENHERTU® Type II Variation Application Validated by EMA for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following At Least One Endocrine Therapy The European Medicines […]

by Sandhya Ramalingam

Continue Reading
Page 2 of 2